Bi Asset Management Fondsmaeglerselskab A Exact Sciences Corp Transaction History

Bi Asset Management Fondsmaeglerselskab A

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$56.27 - $73.77 $13,392 - $17,557	-238 Reduced 4.17%	5,475 $378,000
Q4 2023 Feb 09, 2024	SELL	$59.06 - $75.72 $2.16 Million - $2.77 Million	-36,605 Reduced 86.5%	5,713 $423,000
Q3 2023 Nov 13, 2023	BUY	$65.94 - $99.04 $2.31 Million - $3.48 Million	35,093 Added 485.72%	42,318 $2.89 Million
Q2 2023 Aug 03, 2023	BUY	$62.68 - $95.05 $290,396 - $440,366	4,633 Added 178.74%	7,225 $678,000
Q1 2023 May 12, 2023	BUY	$47.19 - $70.77 $12,977 - $19,461	275 Added 11.87%	2,592 $176,000
Q4 2022 Feb 13, 2023	BUY	$30.35 - $53.15 $70,320 - $123,148	2,317 New	2,317 $115,000
Q4 2020 Feb 12, 2021	SELL	$99.61 - $142.12 $27,392 - $39,083	-275 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$72.92 - $102.01 $20,053 - $28,052	275 New	275 $28,000
Q4 2019 Mar 19, 2020	SELL	$77.66 - $99.74 $982,554 - $1.26 Million	-12,652 Closed	0 $0
Q3 2019 Mar 19, 2020	BUY	$90.37 - $122.49 $1.14 Million - $1.55 Million	12,652 New	12,652 $1.14 Million

610

166M

1.93M

1.23M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $12B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.